Federal grants to Tiba Biotech LLC
Tiba Biotech LLC in Cambridge, Massachusetts received $4.2 million in federal grants from fiscal 2021 to 2025, across 5 awards. Its largest program was Allergy and Infectious Diseases Research, with $3.8 million. In fiscal 2025 it was awarded $1.4 million.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$4.2 million
- Awards5
- Awarded in FY 2025$1.4 million
- Largest award$2.9 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 1 | $278,957 |
| FY 2022 | 2 | $584,906 |
| FY 2023 | 1 | $966,637 |
| FY 2024 | 1 | $965,678 |
| FY 2025 | 2 | $1.4 million |
Programs that fund Tiba Biotech LLC
| Program | Awards | Amount |
|---|---|---|
| Allergy and Infectious Diseases Research | 4 | $3.8 million |
| Cancer Treatment Research | 1 | $399,300 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 5 | $4.2 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Rapid response to pandemic influenza via multi-antigen rna-based vaccine - project abstract avian influenza a H7N9 causes severe respiratory illness with a high mortality rate, and its zoonotic capacity has raised serious concerns over the possibility of a pandemic. The value of vaccines for pandemi | Allergy and Infectious Diseases Research | September 5, 2023 | $2.9 million |
| Targeted delivery of tumor antigen esarna to the spleen for cancer immunotherapy - project summary this application is in response to notice of special interest (NOSI) NOT-AI-24-007 (rna delivery technologies to allow speciflc tissue target homing) to support the development of non-viral technologie | Cancer Treatment Research | September 8, 2025 | $399,300 |
| Low-dose rna vaccine platform for tickborne flaviviruses - this proposal is to develop a high potency, low-dose powassan virus (POWV) rna vaccine candidate using tiba biotech’s innovative replicon rna delivery system. As the geographical range of ticks grows due to climate change, the incidence of t | Allergy and Infectious Diseases Research | June 15, 2022 | $300,000 |
| Rapid response to pandemic influenza via multi-antigen rna-based vaccine - project summary the proposal is to develop an rna-based, rapid-response influenza vaccine prototype, supporting niaid’s call for nucleic acid-based vaccines that protect against pandemic influenza threats. Avian influenza a h | Allergy and Infectious Diseases Research | February 10, 2022 | $284,906 |
| Rna-based multi-antigen vaccine for SARS-COV-2 - project summary/abstract (30 lines) the proposal is to develop an rna-based multi-antigen SARS-COV-2 vaccine, supporting niaid’s call to develop a vaccine using emerging antigen design strategies and novel delivery approaches. The SARS-COV-2 pandemic | Allergy and Infectious Diseases Research | April 29, 2021 | $278,957 |
Questions people ask
How much federal grant money does Tiba Biotech LLC get?
$4.2 million in 5 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Tiba Biotech LLC the most?
The Department of Health and Human Services, with $4.2 million in 5 awards.
What is Tiba Biotech LLC's largest federal grant?
$2.9 million under Allergy and Infectious Diseases Research, with its first action in the period on September 5, 2023. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Tiba Biotech LLC?
Its largest are Allergy and Infectious Diseases Research and Cancer Treatment Research.
Other grant recipients in Cambridge
- Massachusetts Institute of Technology
- President and Fellows of Harvard College
- The Broad Institute, Inc
- National Bureau of Economic Research Inc
- Smithsonian Institution
- City of Cambridge
- Whitehead Institute for Biomedical Research
- Ada Forsyth Institute, Inc.
Largest federal grant recipients in Massachusetts · Federal grants in Massachusetts